Pieris Pharmaceuticals has been granted a patent for a novel library and muteins derived from human lipocalin 2 (Lcn2, hNGAL) that bind specific targets with detectable affinity. These muteins can be used to deplete pathological biomolecules like amyloid beta peptide in Alzheimer’s disease or target tumor neovasculature. GlobalData’s report on Pieris Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Pieris Pharmaceuticals, Active contour based diagnosis models was a key innovation area identified from patents. Pieris Pharmaceuticals's grant share as of January 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for novel muteins derived from human lipocalin
A recently granted patent (Publication Number: US11827681B2) discloses a novel human neutrophil gelatinase-associated lipocalin (hNGAL) mutein with specific mutations at various amino acid sequence positions. The mutein is designed to bind to a target with detectable affinity, particularly to non-natural ligands that do not interact with the native hNGAL under physiological conditions. The mutations in the mutein involve amino acid replacements at specific positions, enhancing its binding capabilities to the target molecules. Additionally, the patent covers various aspects of the mutein, including conjugation to different compounds, fusion with other proteins or peptides, and methods for its production.
Furthermore, the patent encompasses nucleic acid molecules encoding the mutein, host cells containing these nucleic acid molecules, and methods for producing the mutein or related products. The production method involves mutagenesis of the nucleic acid encoding mature hNGAL to introduce the desired mutations, followed by expression of the mutein product. The patent also highlights the potential applications of the mutein in various fields, including diagnostics, therapeutics, and research. Overall, the patent provides a comprehensive framework for the development and utilization of the hNGAL mutein, offering a promising avenue for further advancements in the field of molecular biology and biotechnology.
To know more about GlobalData’s detailed insights on Pieris Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
